Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
His shareholder support is second to none - I just filled a buy order in support of his support and it feels very supportive!
Spoke too soon... or he listens to his shareholders. Little of both prolly
So all will be well in time - our great^1666667 grandchildren (that's 1666667 greats in front of grandchildren) will have evolved to have as many p53 genes as elephants! If we end up talking about generations that span 50million years maybe we should come up with a log-child or something. Because saying your 14.326th log-child (1e^14.326 = 1666106) is much quicker than saying great 1666667 times. Oh, I digress...
Haha
Time to post comments to this article, get some new eyes on Cellceutix...
Yep, good post. There are multiple trials nearing significant milestones that will bring the buyers back. Question is, do you want in before everyone hears, or after everyone hears about it? Without the ability to sit on the button all day, I just buy and wait. Cash and financing are in place so that waiting is no problem at all. And no, Leo won't use up all $30 million available to him beyond the $8 million cash at this low price. By the time the $8 million cash is getting low, Kevetrin phase 1 will be complete, maybe Prurisol and Brilacidin-OM as well, maybe Brilacidin Phase 3 beginning. With all that up and coming the stock price is going to rise significantly.
At least Leo isn't running his mouth like a rookie!
Kevetrin solves all our problems, meeting primary and secondary endpoints, which is all but guaranteed.
The Cellceutix CEO does a fantastic job keeping his shareholders updated as corporate milestones are met, new initiatives are considered, and as some initiatives are moved up or down the list of corporate priorities within a changing regulatory landscape and within a pipeline that is consistently evolving by way of pre-clinical studies performed by a very talented staff and/or highly respected research universities and institutions.
A list of Press Releases shows the frequency with which the CEO communicates with his shareholders:
09/16/15 Cellceutix Announces Brilacidin Data to be Presented by ICPD at The Joint 55th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC)
09/14/15 Cellceutix Announces Filing of its Annual Report on Form 10-K
09/08/15 Cellceutix Plans for Phase 2 Clinical Trial in Ovarian Cancer
08/24/15 Cellceutix Requesting Meeting with FDA on Kevetrin for Pediatric Retinoblastoma
08/20/15 Cellceutix’s Clinical Trial of Anti-Cancer Agent Kevetrin Meeting Its Goals, Approaching End of Trial
08/11/15 Cellceutix’s Kevetrin and Thymoma — a Rare Cancer
08/10/15 Cellceutix: Thank You
08/07/15 Cellceutix Provides Insights to its Four Clinical Trials for the Treatment of ABSSSI (Completed Phase 2), Anti-Cancer (Phase 1), Psoriasis (Phase 2), and Oral Mucositis in Head and Neck Cancer Patients (Phase 2)
08/06/15 Cellceutix Commences Phase 2 Trial of Prurisol as New Treatment for Psoriasis
08/03/15 Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
07/20/15 Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
07/15/15 Cellceutix’s Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
06/08/15 Cellceutix Provides Update on Uplist Application
06/03/15 Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
06/01/15 Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
05/28/15 Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
05/25/15 Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
05/22/15 IRB Approves Additional Enrollment in Cellceutix’s Clinical Trial of New Cancer Drug Candidate for Solid Tumors
05/13/15 Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
04/27/15 Cellceutix Selects Independent Directors and Committee Members
04/21/15 Cellceutix Provides Corporate Update
04/13/15 Cellceutix PIND Meeting Scheduled with FDA for Hidradenitis Suppurativa
04/01/15 Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement
03/24/15 Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
03/16/15 Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
03/02/15 Cellceutix To Expand its Skin Product Pipeline
01/27/15 Cellceutix Enthusiastic About Proposed Budget Increase to $1.2 Billion to Fight Drug-Resistance Bacteria
01/26/15 Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
01/22/15 Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
01/20/15 Cellceutix Reports Spleen Lesion ‘Disappears’ in Patient with Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
01/11/15 Cellceutix Invites All to Attend Company’s Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
01/05/15 Cellceutix Releases Confidence Interval Statistics Showing Clinical Success Rates for Brilacidin in Treatment of ABSSSI
12/29/14 Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
12/22/14 Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
12/10/14 Cellceutix: Prurisol™ for Psoriasis — FDA Agrees That Phase 2 Study May Begin
12/08/14 Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
11/24/14 Cellceutix: December to Be Momentous Month in Company’s History
11/10/14 Patient Enrollment in Cellceutix Phase 01/01/00 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 07/06/05
10/31/14 Cellceutix’s New Chief Operating Officer Dr. James Alexander Addresses Shareholders
10/23/14 Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
10/13/14 Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site For Phase 2 Clinical Trial Of New Treatment For Oral Mucositis
09/28/14 Cellceutix Provides Update to Shareholders
09/19/14 Cellceutix to President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat to Public Health
09/09/14 Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
09/05/14 Cellceutix to Present at Rodman & Renshaw’s 16th Annual Global Investment Conference
09/02/14 Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
08/19/14 Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
08/11/14 Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
08/07/14 Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial
08/04/14 Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected this Month
07/14/14 Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
07/07/14 Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs)
06/23/14 Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
06/16/14 Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
06/02/14 Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
05/27/14 Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities
05/19/14 Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market
05/12/14 Cellceutix Confident in Its Formidable Antibiotic Arsenal
05/05/14 Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis
04/14/14 Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae
04/01/14 Cellceutix Comments On Positive FDA Advisory Vote For Dalbavancin And Tedizolid
03/31/14 Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
03/24/14 Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
03/21/14 Cellceutix to Initiate Psoriasis Clinical Trial
03/19/14 Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
03/10/14 Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial
03/05/14 Cellceutix Expands to Gram-Negative Bacterial Infections
02/25/14 Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
02/24/14 Cellceutix Selects Dr. Reddy’s Laboratories For Formulation of Brilacidin for Ophthalmic and Otitis Infections
02/18/14 Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Underway in Phase 2b Clinical Trials of Brilacidin
02/03/14 Cellceutix Files with FDA for Phase 2b Clinical Trial of Novel Antibiotic Brilacidin; Enrollment of Patients Expected to Start Mid-February
01/21/14 Cellceutix Sees Increased Valuation Potential for its Novel Antibiotic Brilacidin
01/15/14 Cellceutix Provides Updates on Clinical Trials and Developments of its Anti-Cancer, Anti-Psoriasis, and Antibiotic Compounds
01/13/14 Cellceutix Corporation to Present at Biotech Showcase 2014
01/06/14 Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol
12/20/13 Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
12/15/13 Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin
12/09/13 Cellceutix Updates on Current Status of Programs
11/18/13 Cellceutix Identifies Drug Candidates for Gram-Negative and Candida Fungal Infections
11/04/13 Cellceutix to Pursue Significant Conjunctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin
10/29/13 Cellceutix Enters Into New $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
10/21/13 Cellceutix Structures for Significant Growth in Upcoming Year
10/14/13 Cellceutix Drug Brilacidin™ May Be The Key Antibiotic on the Horizon for Serious Skin Infections; Plans to Start Phase 2b Study in January 2014
10/10/13 Cellceutix Antibiotic Brilacidin Chosen by Elsevier as “Top Project to Watch” in Infectious Disease
10/02/13 Cellceutix Completes Final Study to File IND Application for New Psoriasis Drug Prurisol
09/24/13 Cellceutix Plans Phase 2b Trial of New Antibiotic, Reports Fifth Cohort Complete in Novel Cancer Drug Clinical Trial
09/15/13 Cellceutix Completes Acquisition Of Polymedix Assets, Immediately Plans Brilacidin™ Phase 2b Clinical Trial For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) and Phase 2 Clinical Trial For Oral Mucositis
09/09/13 Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
08/12/13 Cellceutix Clinical Study on its Anti-Psoriasis Drug Prurisol™ to Commence
06/26/13 Cellceutix Signs Material Transfer Agreement for Research of Kevetrin in Lymphoma and Multiple Myeloma Cancers With Major Cancer Center
06/14/13 Cellceutix Reports Kevetrin™ Dosing Increases and Prurisol™ Anti-Psoriasis Drug Stability Tests Underway
06/03/13 Cellceutix Presents Poster at ASCO on its Clinical Trial of Anti-Cancer Drug Kevetrin
05/28/13 Cellceutix to Present Poster on Novel Anti-Cancer Drug at Annual ASCO Meeting
04/05/13 Coach Jim Boeheim Putting Up His Best Defense Against Michigan…and Cancer
03/29/13 Cellceutix Selected for Poster Presentation on Kevetrin at 2013 ASCO Meeting
03/08/13 Cellceutix Plans for Future Trials Aimed at the Latest Initiatives of ‘Breakthrough’ Designation by the Food and Drug Administration
03/04/13 Cellceutix Signs with Leading Cancer Center For Licensing New Drug
02/22/13 Cellceutix Reports on Kevetrin Clinical Trials and Prurisol Manufacturing
02/01/13 Cellceutix Abstract for Annual American Society of Clinical Oncology Meeting
01/24/13 Cellceutix Reports In Vivo Tumor Shrinkage in Renal Cancer
01/06/13 Cellceutix Announces A Study Planned At The University Of Bologna Titled “A Multi-Center, Open-Label, Phase Ib Study Of Kevetrin With Cytarabine In Patients With Acute Myelogenous Leukemia (AML)” ; U.S. Patent Issued for Kevetrin, Cellceutix’s p53 Anti-Cancer Compound
12/30/12 Cellceutix CEO Discusses Corporate Developments in 2012 And Plans For 2013
12/23/12 Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
12/14/12 Cellceutix Announces Kevetrin Dosing Levels Increased as Clinical Trials Advance
12/09/12 Cellceutix Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
11/30/12 Cellceutix Anti-Cancer Drug Kevetrin Completes Dosing Cycle, Ready for Next Cohort
11/09/12 Cellceutix Signs Agreement for Clinical Trial in Europe on New Psoriasis Drug
11/07/12 Cellceutix Hits Major Milestone in Company History; Dosing Underway for New Cancer Drug at Leading Hospitals
10/29/12 First Patients Recruited and Enrolled in Cellceutix Clinical Trial of Novel Anti-Cancer Drug Kevetrin
10/19/12 Clinical Trials for Cellceutix Novel Anti-Cancer Drug Now Active at Leading Hospitals
10/05/12 Clinical Trials Going Active for Cellceutix Anti-Cancer Drug Kevetrin
09/21/12 Cellceutix to Commence Clinical Trials for its Novel Anti-Cancer Drug Kevetrin
09/07/12 Cellceutix Plans for European Funded Leukemia Phase 1 Trial
08/30/12 Cellceutix Anti-Psoriasis Drug Advances Toward Phase 2 Clinical Trials With Selection of Dr. Reddy’s Laboratories For Manufacturing
08/06/12 Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber for Start of Clinical Trials
07/23/12 Cellceutix Cancer Trial Enrollment Planned for August 2012
07/16/12 Cellceutix Meets Manufacturers to Synthesize Psoriasis Drug Candidate for Clinical Trials; Site Initiation Visit for Clinical Trials of Kevetrin to Happen This Week
07/09/12 Cellceutix Sets for Cancer Patient Enrollment in Clinical Trial of Pioneering p53 Cancer Drug
06/26/12 Cellceutix Novel Anti-Cancer Drug Kevetrin™ Receives IRB and SRC Approvals for Clinical Trials at Harvard’s Dana-Farber Cancer Institute
06/22/12 Cellceutix Approved by FDA to Proceed With Clinical Trials on Novel Cancer Drug
06/18/12 Cellceutix Preparing for Phase 2 Clinical Trials With New Psoriasis Drug
06/13/12 Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Approach for Its Psoriasis Drug
05/30/12 Cellceutix Adds Brain Cancer to Growing List of Indications for Its Novel Cancer Drug
05/21/12 Cellceutix Files Amended IND With FDA for Its Novel p53 “Guardian Angel” Anti-Cancer Drug
05/14/12 Cellceutix Arranges $1 Million Financing for Clinical Trials of New Cancer Drug; IND Filing Imminent
05/07/12 Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer
04/16/12 FDA Schedules Meeting With Cellceutix on New Psoriasis Drug
04/04/12 Cellceutix Novel Anti-Cancer Compound Kevetrin™ Presented at American Association for Cancer Research Annual Meeting
03/19/12 Cellceutix Enters Into a Collaborative Agreement With Beth Israel Deaconess Medical Center for Pro-Apoptotic Function of p53 in Melanoma and Renal Cell Carcinoma
03/12/12 Cellceutix Files Pre-IND Documentation to FDA for New Psoriasis Drug
02/27/12 Cellceutix ‘Back in the Game’ With cGMP Manufacturing Completed on New Cancer Drug
01/23/12 Cellceutix Featured on Cover of Prominent Business Journal
01/17/12 Cellceutix Anti-Cancer Drug Shown to Regulate HDAC2, a Major Therapeutic Target for Treatment of a Broad Range of Cancers
01/03/12 Cellceutix Ushers in 2012 With Plans for Clinical Trials for Anti-Cancer and Psoriasis Drugs
12/13/11 Cellceutix Provides Updates on IND for Cancer Drug, Initiates Collaborative Agreement With Pioneer Valley Life Sciences Institute for Mitochondrial Research
11/28/11 Dr. Paul Marks Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents to Protect Kevetrin™
11/07/11 Cellceutix Files Investigational New Drug Application (IND) With FDA, Clinical Trials Planned at Dana-Farber/Harvard Cancer Center
10/25/11 Cellceutix to File Investigational New Drug Application for Novel p53 Anti-Cancer Drug
10/17/11 Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested
10/10/11 Prostate Cancer Joins Growing List of Cancers That Succumb to Cellceutix Corporation’s Potent Anti-Cancer Drug
10/03/11 Cellceutix’s Drug Discovery Is a Major Leap Forward in the Fight Against Cancer
09/26/11 Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug
09/21/11 Cellceutix Signs Lab Services Research Support Agreement With Dana Farber/Partners CancerCare, Inc.
08/01/11 With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug
07/19/11 Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial
06/27/11 Cellceutix Provides Updates on Kevetrin™, Cellceutix’s Novel Anti-Cancer Therapy
06/20/11 Cellceutix’s Kevetrin™ Slows Pancreatic Cancer Tumor Growth by 94%; Protocol Towards Clinical Trials Nearing End
06/06/11 Vendor Showcases Kevetrin™, Cellceutix’s Anti-Cancer Drug at American Society for Mass Spectrometry Meeting
05/23/11 Cellceutix CEO States “Full Speed Ahead”
05/16/11 Cellceutix Announces Kevetrin™ in Combination With Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study
05/09/11 Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site
05/03/11 Insight Into Cellceutix Corporation’s Breakthrough Cancer Compound
04/25/11 Cellceutix Cancer Drug Trumps Competitors
02/28/11 Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the “Guardian Angel of the Human Genome”
02/14/11 Cellceutix Announces Settlement With Former CEO
11/09/10 Cellceutix Announces Departure of George W. Evans as CEO
11/04/10 Cellceutix Receives Federal Grants for Each of Its Active Research Programs; Total Exceeds $730,000
10/28/10 Cellceutix Completes Final Toxicity Study for Its Cancer Compound; United States Food and Drug Administration IND Application Underway
09/28/10 Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment of Resistant Lung and Breast Cancers
08/24/10 Cellceutix Closing in on Human Trials with Kevetrin™ for Drug-Resistant Cancers as the Company Reports Progress on Toxicity Studies
07/26/10 Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound
07/07/10 Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application
06/23/10 Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain
06/21/10 Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells
06/14/10 New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes; Chief Scientific Officer Sees Potential for Company to Emerge as Industry Leader as Pharmas Strive for Revolutionary Autism Treatments
06/07/10 Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound
06/03/10 Cellceutix CFO Discusses Autism Drug, Kevetrin™ and Company Progressions With CEOCFO Interviews and News
05/24/10 Cellceutix Signs Agreements for Kevetrin™ Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers
05/18/10 Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer Compound
05/12/10 Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer and Novartis Announcements Indicate Interest in Autism by Major Companies
04/21/10 Cellceutix Presents Poster Session at AACR; Important New Data on Kevetrin™ in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance With Second Cycle
This intelligent post is refreshing, thanks. Impatience is not a trait anyone should advertise so foolishly, esp. for an investment community board, esp. for a biotech investment, CTIX is no different.
A new era of lawyers suing lawyers and the beginning of a self-regulated system? Could be a beautiful thing if it is proven advantageous to counter-sue frivolous lawsuits. I might add my name to the list as well.
"They wouldn't get past the fact that the company in question is on the Pink Sheets to look at the science in most cases."
You've demonstrated your ability to judge CTIX's future prospects based on the past performance of different securities, but I'm wondering what type of data/events/etc you consider to be the exception to 'in most cases'.
Current funding lasts a lot longer than May, or did you mean May 2017?
"We currently have an approximate $8.4 million cash balance in the bank..."
"Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company's common stock over the 36-month term of the Purchase Agreement. As of June 30, 2015, the available proceeds from Aspire is $29.7 million. "
"We expect to incur costs of approximately $17.7 million in the upcoming twelve (12) months to operate our business"
http://www.sec.gov/Archives/edgar/data/135525...ix_10k.htm
Can't argue with the facts! Nice straightforward post on the undeniable progress that has been made and the rise in shareholder equity. Onward and upward!
Luckily we are a good 2 years away from 'flirting with cash problems'. You did read the 10K, yeah?
"We currently have an approximate $8.4 million cash balance in the bank..."
"Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company's common stock over the 36-month term of the Purchase Agreement. As of June 30, 2015, the available proceeds from Aspire is $29.7 million. "
"We expect to incur costs of approximately $17.7 million in the upcoming twelve (12) months to operate our business"
http://www.sec.gov/Archives/edgar/data/1355250/000147793215005843/ctix_10k.htm
$38.1 million available to do $17.1 million of work in the next year, which includes:
- Brilacidin Phase III (leading to a lucrative partnership)
- Kevetrin Phase I completion (possibly leading to a lucrative partnership)
- Purisol Phase II completion (possibly leading to a lucrative partnership)
- Brilacidin-OM Phase II completion (possibly leading to a lucrative partnership)
- beginning of Kevetrin Phase II AML - paid for by University of Bologna(possibly leading to a lucrative partnership)
- beginning of Kevetrin Phase II Ovarian alone and in combination (possibly leading to a lucrative partnership)
- beginning of Kevetrin Phase I for pediatric retinoblastoma
- completion of gram-negative preclinical studies on HPD mimetics
- more
I have never heard of a management team with the ability to take a drug all the way to phase three and two others all the way to phase two on less than 13million (2015 inflation adjusted) dollars per year. And two of these a whole new class of compound, one antibiotic, one cancer. Talk about fantastic product advancement skills with fabulous connections to leading researchers. Unheard of, simply amazing Cellceutix team!
I know of at least one situation in the past where a stock uplisted to NASDAQ while being below $2, the explanation was that qualification occurred during a period when the pps was above $2. This might just be wishful thinking, but if audited financials is what NASDAQ has been waiting for, might the pps timeframe of question fall within the same audited financial timeframe? CTIX was well above $2 for months leading up to fiscal year end - could we uplist next week???
Hmm... Something rare occurring? eom
I believe it! Best CEO in my portfolio by far. Just look at our peers - vtae dropped over 65% from over $22 to low $7 in 8 months, then explodes 100% in a day on phase one news. CTIX has just as much potential to explode 100% in one day. However, add Brilacidin phase three, Prurisol phase two, Brilacidin-OM phase two, etc. Get a grip and do some research on your investments man!
It's a Mexican standoff - one party is going lose big when Leo comes calling!
Thanks Sox for your relevant posting, and might I add take a lesson from it - this board is for more than just complaining. You cannot deny there are some amazing things transpiring at Cellceutix and in the hospitals around the country using several of Cellceutix's compounds on patients, patients who have without a doubt received benefit (like all the 100% response rate ABSSI patients alive without that lethal infection today). Yet these things we have knowledge of are mentioned less than the behind-the scene confidential management aspects we know nothing about? Laughable.
I'd better get my final buy on! The est completion date for primary outcome measures is DEC 2015, that includes MTD at 6 mo. (which is now irrelevant) and DLT at 4 weeks. The P21 biomarker final collection point is at 24 hours after dose. End of may was IRB approval for final 40 patients leaving plenty of time for 1 month and 2 month secondary outcome measures of tumor serum level and tumor size. Wow, this is really getting me excited again! Thanks
Ha. There are 3 options on a CTIX opinion like that: 1) we are on antidepressants and they're working, 2) they are on antidepressants and they're not working, 3) they need to be on antidepressants. But since 1) is not mutually exclusive, it can be ignored. Because 2) is mutually exclusive of 3), I give it a 50% chance 2 is true, a 50% chance 3) is true, and a 100% chance either 2) or 3) is true.
Go CTIX!
Not sure that it sums that way -
The fails to deliver for July, still waiting on the data to be released for the first half of August...
http://www.sec.gov/foia/docs/failsdata.htm
SETTLEMENT DATE|CUSIP|SYMBOL|QUANTITY (FAILS)|DESCRIPTION|PRICE
20150701|15115V101|CTIX|4943|Cellceutix Corporation Common |2.58
20150702|15115V101|CTIX|6386|Cellceutix Corporation Common |2.58
20150706|15115V101|CTIX|7219|Cellceutix Corporation Common |2.56
20150707|15115V101|CTIX|27814|Cellceutix Corporation Common |2.54
20150708|15115V101|CTIX|37636|Cellceutix Corporation Common |2.49
20150709|15115V101|CTIX|53731|Cellceutix Corporation Common |2.61
20150710|15115V101|CTIX|64486|Cellceutix Corporation Common |2.56
20150713|15115V101|CTIX|211|Cellceutix Corporation Common |2.64
20150714|15115V101|CTIX|14053|Cellceutix Corporation Common |2.64
20150715|15115V101|CTIX|20740|Cellceutix Corporation Common |2.64
20150716|15115V101|CTIX|17353|Cellceutix Corporation Common |3.02
20150717|15115V101|CTIX|18813|Cellceutix Corporation Common |3.06
20150720|15115V101|CTIX|12892|Cellceutix Corporation Common |3.36
20150721|15115V101|CTIX|4673|Cellceutix Corporation Common |3.54
20150722|15115V101|CTIX|11550|Cellceutix Corporation Common |3.36
20150723|15115V101|CTIX|42707|Cellceutix Corporation Common |3.27
20150724|15115V101|CTIX|4485|Cellceutix Corporation Common |3.17
20150728|15115V101|CTIX|161|Cellceutix Corporation Common |3.02
20150729|15115V101|CTIX|9320|Cellceutix Corporation Common |2.90
20150730|15115V101|CTIX|45231|Cellceutix Corporation Common |2.78
20150731|15115V101|CTIX|5000|Cellceutix Corporation Common |2.71
Grant money working for our HDP platform: http://projectreporter.nih.gov/project_info_description.cfm?aid=8871683&icde=0
$0.75M
Wow - it's awesome that we picked up the whole definsin mimetic platform after the discovery, initial research, developmental, pre-clinical, phase I, and phase IIa had all been completed. We'll get those Billions of revenue for only spending a small fraction of the Billion to get to approval! Thanks for that great news! Great job Leo and Menon on that move.
Leo's shareholder support is unmatched, it has been apparent for the 4+ years I've been growing my share count and it's an awesome characteristic to have in a CEO, wish more of my investments had his style.
No, like I said - there is any number of reasons to sell, even if a significant approval was imminent. Some are court ordered, some because personal financial situations give very limited liquidy options, etc, etc.
Andy - I'm guessing there are lots of places increasing orders. Now, I can only think of one reason to increase your orders - product demand is increasing. Cytosorb is either becoming a fad, the newest style in treatment, or it is providing benefit to providers and patients. I guess companies make profit on each of those, I'm guessing it's the clinical benefit tho. Thanks.
Do we really need to go over this again? Nice attempt at seeding fear again, but it's common knowledge that nothing can be deemed from insiders selling small portions on regular intervals because who knows - divorce settlement requirments, alimony payments, new multimillion dollar home, could be lots of reasons. The only information from insider transactions that can be reliably interpreted is insider buys. Period. There is only one reason to buy, there is any number of reasons to sell.
It actually is a pretty good contrarian indicator if you look back. The 10Q gets released, BMA says it's going to drop, and now we're hitting new 90 day highs. It's either an attempt to influence or just bad judgment, I'm not sure which.
They doubled their cash and revenue - I'll take it. Growth is what matters, even if it isn't fast enough for all the short term investors out there. Net income went from negative to positive. I think it's positive, for my time horizon.
Exactly why I stated that it will be interesting to see the next data sets, to see if there are any significant gradients in the date stream, esp. near the recent event (plus the 3 day delivery requirement). I did not explain that, so thanks.
cnsfails201507a.txt, http://www.sec.gov/foia/docs/failsdata.htm :
SETTLEMENT DATE|CUSIP|SYMBOL|QUANTITY (FAILS)|DESCRIPTION|PRICE
20150714|15115V101|CTIX|14053|Cellceutix Corporation Common |2.64
20150713|15115V101|CTIX|211|Cellceutix Corporation Common |2.64
20150710|15115V101|CTIX|64486|Cellceutix Corporation Common |2.56
20150709|15115V101|CTIX|53731|Cellceutix Corporation Common |2.61
20150708|15115V101|CTIX|37636|Cellceutix Corporation Common |2.49
20150707|15115V101|CTIX|27814|Cellceutix Corporation Common |2.54
20150706|15115V101|CTIX|7219|Cellceutix Corporation Common |2.56
20150702|15115V101|CTIX|6386|Cellceutix Corporation Common |2.58
20150701|15115V101|CTIX|4943|Cellceutix Corporation Common |2.58
http://www.sec.gov/investor/pubs/regsho.htm :
Selling stock short and failing to deliver shares at the time of settlement with the purpose of driving down the security’s price. This manipulative activity, in general, would violate various securities laws, including Rule 10b-5 under the Exchange Act.
Whether this is illegal shorting going on or not, it will be interesting to see the next sets of data end of July and early Aug.
All this information is such a beautiful thing! All of the 'confused' posters can just simply be pointed to the great CTIX Press Release of August 7, 2015.
Yes, the real news. Prurisol phase II started and now there is potential news on active K, active P, and active B-OM. Any of which can highlight some significant fundamental progress. Three separate blockbusters on the verge of efficacy announcements and a potential proof of 'viability' into the extremely lucrative antiinflammatory market. All is well on the science side, the pps side WILL follow eventually.
Orchestrated drop prior to partnership??? eom ;)
The resilience of CTIX long must scare the willys out of shorts.
Glad I only got partial fills yesterday - finishing those purchases off at a better price ain't so bad